STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
STAT News · LC · trust 45/100
The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis
Read the original at STAT News →
Open in TruthVane →